Drug intelligence / Profile preview

F03-50

Development stage: Preclinical
Lead developer: Feromics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

F03-50 is a preclinical-stage chimeric antigen receptor T-cell (CAR-T) therapy being developed by Feromics. The asset is built upon the company's proprietary ID-CAR-T (Immune-Directed CAR-T) platform, which is designed to enhance the therapeutic potential of cell therapies. As of 2024, Feromics has not publicly disclosed the specific molecular target or the primary disease indication for F03-50, though the program is currently in the preclinical phase of development.

Beyond the preview

Go deeper on F03-50.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F03-50.

Explore the full profile